EU to launch fast-track pilot for breakthrough medical devices and in vitro diagnostics

Measuring and reducing surgical staff stress in a realistic operating room setting using EDA monitoring and smart hearing protection

BackgroundStress is a critical factor in the operating room (OR) and affects both the performance and well-being of surgical staff. Measuring and mitigating this stress

A Peer-Led, Nurse-Involved Blended Online and Offline Peer Support Program (PNO2PSP) for Psychosocial Adjustment in Young- to Middle-Aged Patients With Breast Cancer: Cluster Randomized Clinical Trial

Background: Young- to middle-aged patients with breast cancer face significant psychosocial challenges. Existing interventions often lack comprehensiveness, timely initiation, and tailoring specific to this population’s

The Need for Continued Investment in Digital Pain Assessment

Post Content

Long-Term Outcomes, Moderators, and Predictors in Online Mindfulness–Based Cognitive Therapy for People With Cancer: Secondary Analysis of a Randomized Controlled Trial

Background: A 3-armed randomized controlled trial (RCT) demonstrated that 2 formats of online mindfulness–based cognitive therapy (eMBCT)—group-blended and individual-unguided—effectively reduced psychological distress and improved positive

Multimodal Intelligent Monitoring of Parkinson Disease: Scoping Review of Progress and Translational Challenges

Background: Parkinson disease (PD) is a progressive neurodegenerative disorder with a rapidly growing global prevalence. Current clinical assessments, such as the Unified Parkinson Disease Rating

The EU will launch a pilot programme in 2026 to accelerate access to breakthrough medical devices and in vitro diagnostics, offering enhanced regulatory support and faster scientific review

Led by the European Medicines Agency, the initiative will provide enhanced regulatory support and priority scientific advice for innovative technologies, while maintaining strict safety and performance standards. The scheme is designed to test a faster approval pathway for high-impact medical innovations and help shape future EU medical device regulations.

EU pilot programme to fast-track breakthrough medical devices with enhanced regulatory support

In the second quarter of 2026, the European Medicines Agency will launch a pilot programme to support breakthrough medical devices and in vitro diagnostics.

The aim is to test a pathway that accelerates patient access to innovative technologies by enabling manufacturers of breakthrough medical devices to participate in a pilot evaluation process, helping them meet the EU’s high standards for safety and performance more quickly.

The manufacturers of designated breakthrough medical devices will gain access to enhanced regulatory support and priority scientific advice from the European Medicines Agency’s medical device expert panels.

EU pilot to shape breakthrough devices rules and speed access

The pilot builds on the recently adopted MDCG Guidance on Breakthrough Devices (MDCG 2025-9). The pilot will shape a future framework for breakthrough medical devices, which the Commission has included in its December 2025 proposal to revise the Medical Devices Regulation and the In Vitro Devices Regulation (new Article 52a of the MDR and new Article 48a of the IVDR).

The guidance sets out a structured pathway for devices that address serious conditions or unmet medical needs, offering manufacturers enhanced regulatory support, including early scientific advice and closer engagement with expert panels and regulators. Rather than lowering approval standards, the approach allows for a more iterative and flexible evidence-building process using a combination of pre-market and post-market data. The aim is to accelerate patient access to transformative medical devices while strengthening Europe’s innovation-friendly regulatory environment.

The initiative is an important step in strengthening Europe’s innovation-friendly regulatory environment for medical technologies. To obtain a breakthrough designation, manufacturers will need to request an opinion from EMA’s expert panels, with further guidance and templates for applicants to be published by EMA ahead of the pilot’s launch. Ultimately, this pilot will drive innovation in critical public health areas and maintain trust in the quality, safety, and performance of advanced medical devices across the EU market.